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Rapid decrease in titer and breadth 
of neutralizing anti-HcV antibodies 
in HiV/HcV-coinfected patients 
who achieved SVR
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Ma Ángeles Jiménez-Sousa1, Josep M. Guardiola5, Manuel crespo  6, ignacio de Los 
Santos7, Miguel A. Von Wichmann8, Ana carrero2,3, María Belén Yélamos9, Julián Gómez9, 
Salvador Resino  1, isidoro Martínez  1 & The GESIDA 3603b Cohort Study Group*
The main targets for neutralizing anti-hepatitis C virus (HCV) antibodies (HCV-nAbs) are the E1 and E2 
envelope glycoproteins. We have studied the characteristics of HCV-nAbs through a retrospective study 
involving 29 HIV/HCV-coinfected patients who achieved sustained virological response (SVR) with peg-
ifnα + ribavirin anti-HCV therapy. Plasma samples at baseline and week 24 after SVR were used to 
perform neutralization assays against five JFH1-based HCV recombinant viruses coding for E1 and E2 
from genotypes 1a (H77), 1b (J4), 2a (JFH1), 3a (S52) and 4a (ED43). At baseline, the majority of plasma 
samples neutralized 1a, 1b, 2a, and 4a, but not 3a, genotypes. Twenty-four weeks following SVR, most 
neutralizing titers declined substantially. Furthermore, titers against 3a and 2a were not detected in 
many patients. Plasma samples with high HCV-nAb titers neutralized all genotypes, and the highest 
titers at the starting point correlated with the highest titers at week 24 after SVR. In conclusion, high 
titers of broad-spectrum HcV-nAbs were detected in HiV/HcV-coinfected individuals, however, those 
titers declined soon after SVR.
Hepatitis C virus (HCV) infection is a serious global health problem. According to a recent WHO report, 71 
million people were living with chronic HCV infection worldwide in 20151. These individuals are at risk of devel-
oping cirrhosis, end-stage liver disease, and hepatocellular carcinoma over time2,3. Despite the impressive efficacy 
of the direct-acting antivirals (DAAs) against HCV infection (>90% achieved sustained virological response 
[SVR]), there are still some problems facing the hope of controlling HCV infection with DAAs alone4. Since 
hepatitis C is largely asymptomatic in the initial stages, less than 20% of HCV-infected individuals worldwide are 
aware that they are infected and only a minority of them have access to anti-HCV treatment and thus, remain at 
risk of transmitting the HCV infection1. Furthermore, those that receive successful DAAs therapy are not pro-
tected against reinfection with HCV5. For these reasons, the development of an effective preventive vaccine will 
provide a useful, cost-effective tool at attempts to control and eradicate HCV infection6.
HCV is a positive-strand RNA virus with a nucleocapsid containing the HCV genome and an envelope 
crowned by the E1and E2 envelope glycoproteins, which are the main targets for neutralizing anti-HCV anti-
bodies (HCV-nAbs)7. Several lines of evidence point to the involvement of HCV-nAbs in protecting from HCV 
infection: a rapid and potent HCV-nAbs response correlates with spontaneous HCV clearance8–12, and the passive 
administration of anti-HCV antibodies prevents HCV infection in experimental animals13–17. Therefore, studies 
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monitoring titers and dynamics of HCV-nAbs are pertinent for designing strategies aimed to protect people from 
HCV infection, particularly in at-risk populations (injecting drug users [IDU] and men who have sex with men 
[MSM], among others).
Both primary HCV infection and HCV reinfections are common among human immunodeficiency virus 
(HIV)-infected individuals within the IDU and MSM groups18,19. However, little is known about the dynamics of 
HCV-nAbs in HIV-infected patients who eliminate HCV infection after HCV therapy.
In this study, we have analyzed the titers, breadth, and dynamic of HCV-nAbs in HIV/HCV-coinfected indi-
viduals before HCV treatment and after achieving SVR with HCV therapy.
Results
patient characteristics at baseline. Table 1 shows the characteristics of each of the 29 HIV/HCV-
coinfected patients at baseline. Overall, the median age was 49 years, 69% were male, 75.9% were IDU, and 27.6% 
had prior acquired immune deficiency syndrome (AIDS)-defining conditions. All patients were on combined 
antiretroviral therapy (cART), and all had undetectable HIV viral load (<50 copies/ml). The median count of 
CD4+ T-cells was 695 cells/mm3 and only eight patients had CD4+ T-cells < 500 cells/mm3. Regarding chronic 
hepatitis C, two patients were F0-F1 (<7.1 Kpa), five were F2 (7.1–9.5 Kpa), eight were F3 (9.5–12.5 Kpa), and 14 
were F4 (≥12.5 Kpa). The median of log10 HCV-RNA was 6.62 IU/ml; 19 patients had log10 HCV-RNA values ≥ 6 
IU/ml; 14 had had previous HCV therapy (median of 92 months before the baseline); and 13 patients were coin-
fected with HCV-GT1a, three with HCV-GT1b, eight with HCV-GT3 and five with HCV mixed infection.
Table 2 shows the characteristics of antiviral therapy in HIV/HCV-coinfected patients during the follow-up. 
All patients were treated with peg-IFNα + ribavirin (RBV), and DAAs were administered to 11 patients 
(Telaprevir to seven patients and Sofosbuvir to four patients). The majority of patients received anti-HCV 
#
Age 
(years) Gender
Previous HCV 
therapy
Time to 
baseline 
(months)
Nadir 
CD4+ T 
(cells/mm3)
Prior 
AIDS IDU
CD4+/
CD8+
CD4+ T 
cells/mm3
HIV-RNA < 50 
cp/mL
HCV 
genotype
Log10 HCV-
RNA (IU/mL)
LSM 
(kPa)
29 45 Male — — 214 Yes No 1.26 814 Yes 1a/2 6.39 6.7
37 55 Male Peg-IFNα/RBV 106 41 Yes Yes 2.32 518 Yes 1a 7.10 9.8
38 42 Male Peg-IFNα/RBV 14 24 Yes Yes 1.00 1053 Yes 1a/4 5.73 17.8
48 49 Female — — 174 Yes No 1.69 916 Yes 3 6.13 35.8
49 53 Male — — 60 Yes Yes 0.83 523 Yes 1a 5.87 10.8
95 48 Female — — 60 No Yes 0.54 280 Yes 1a/1b 6.04 20.6
96 53 Male — — 260 No Yes 0.93 530 Yes 3 7.18 9.5
97 52 Male Peg-IFNα/RBV 120 675 No Yes 1.09 810 Yes 1a 6.76 11.9
103 54 Male Peg-IFNα/RBV 28 90 No No 0.98 348 Yes 1b 4.54 21.3
109 46 Female Peg-IFNα/RBV 99 150 No Yes 1.35 896 Yes 1a 6.69 24.8
114 36 Male — — 314 No No 0.87 887 Yes 1a 6.49 8.8
115 52 Male — — 277 No No 0.99 706 Yes 3 7.17 10.1
133 45 Male — — 421 No Yes 1.38 695 Yes 3 7.00 4.9
139 57 Male — — 48 Yes Yes 0.70 447 Yes 1a 4.36 7.9
148 53 Male IFNα/RBV 86 234 No Yes 0.81 372 Yes 1a 5.83 7.8
174 40 Female — — 122 No Yes 0.84 662 Yes 4/1a 6.46 13.8
213 50 Male — — 323 No Yes 0.79 1210 Yes 3 6.47 25.4
216 50 Female — — 117 No Yes 2.12 1008 Yes 3/4 6.23 10.4
432 49 Female — — 154 Yes Yes 1.40 925 Yes 3 5.74 7.6
515 47 Male Peg-IFNα/RBV 23 84 No Yes 0.44 390 Yes 3 6.38 39.1
711 47 Male — — 46 No Yes 2.09 200 Yes 1a 6.00 12.8
718 44 Female Peg-IFNα/RBV 47 196 No No 0.87 578 Yes 3 6.11 13.4
719 46 Male — — 383 No Yes 0.96 631 Yes 1a 4.76 11.4
721 53 Female IFNα/RBV 17 21 No Yes 1.00 210 Yes 1a 6.62 11.8
722 51 Male Peg-IFNα/RBV 22 162 No No 0.96 724 Yes 1b 6.67 18.0
724 53 Male IFNα/RBV 93 214 No Yes 1.96 446 Yes 1a 5.54 27.7
725 47 Male Peg-IFNα/RBV 101 225 No Yes 1.28 1274 Yes 1a 6.46 14.5
726 43 Female Peg-IFNα/RBV 67 303 No Yes 1.26 762 Yes 1a 5.67 10.2
729 47 Male IFNα/RBV 68 261 Yes Yes 1.33 1218 Yes 1b 6.46 13.2
Table 1. Epidemiological and clinical characteristics at baseline of the HIV/HCV-coinfected patients included 
in the study. Abbreviations: AIDS, acquired immune deficiency syndrome; IDU, injecting drug user; HCV, 
hepatitis C virus; HCV-RNA, HCV plasma viral load; HIV, human immunodeficiency virus; HIV-RNA, HIV 
plasma viral load; LSM, liver stiffness measure; kPa, kilopascals; IFNα, interferon-alpha; peg-IFNα, PEGylated 
interferon-alpha; RBV, ribavirin.
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treatment for 48 weeks. In addition, all patients were treated against HIV infection. At the end of follow-up, the 
median of CD4+ T-cells was 827 cells/mm3, and only seven patients had HIV viral load >50 copies/ml.
Potency and breadth of neutralizing antibodies against HCV chimeric viruses. Plasma samples 
from 29 HIV/HCV-coinfected patients were screened for neutralization potency and breadth against a panel of 
five JFH1-based chimeric HCVs expressing E1and E2 glycoproteins from 1a (H77), 1b (J4), 2a (JFH1), 3a (S52) 
and 4a (ED43) genotypes (see Supplementary Fig. 1). Most plasma samples were able to neutralize 1a (H77), 
1b (J4), 2a (JFH1), and 4a (ED43) viruses with variable potency, both at baseline and 24 weeks after SVR, while 
S52 (3a) was only minimally neutralized, in accordance with previous reports20. Furthermore, patients infected 
with a particular HCV genotype did not show higher neutralization titers against the chimeric virus containing 
glycoproteins from the same genotype compared to the other chimeric viruses carrying glycoproteins from a 
different genotype (see Supplementary Fig. 1). In other words, similar patterns of neutralization were observed 
in most of the patients, regardless of the infecting genotype. To confirm that the genetic distance between the 
viruses did not correlate with the neutralization pattern of the corresponding plasma samples, the E1E2 genes 
from eight patient-derived 1a viruses were amplified and sequenced. All eight sequences clustered with H77 (1a) 
and other 1a viruses (Supplementary Fig. 2). However, the corresponding plasma samples had higher HCV-nAb 
titers against J4 (1b) and ED43 (4a) than against H77 (1a) (Supplementary Fig. 1), confirming that there was no 
correlation between the genetic distance between the infecting viruses and the neutralizing capacity of the anti-
bodies from the infected individuals.
The neutralization potency against recombinant viruses was quantified by the AUC (see Supplementary 
Table 1) and the ID50 (see Supplementary Table 2). At baseline, median values for both AUC (Fig. 1A) and ID50 
(Fig. 1B) had the following decreasing order of potency: J4 (1b) > ED43 (4a) > H77 (1a) > JFH1 (2a) > S52 (3a). 
HCV therapy Antiretroviral therapy
HIV biomarkers at the 
end of study
Patient # IFNα therapy DAAs
Time on HCV 
therapy (wks.) cART Drug #1 Drug #2 Drug #3
CD4+ T 
cells/mm3
HIV-RNA 
(copies/mL)
29 Peg-IFNα/RBV — 48 2PI + II Atazanavir/r Raltegravir 1177 224
37 Peg-IFNα/RBV — 48 2NRTI + NNRTI Abacavir Lamivudine Etravirine 827 <50
38 Peg-IFNα/RBV Telaprevir 48 2PI + II Atazanavir/r Raltegravir 955 <50
48 Peg-IFNα/RBV — 48 NNRTI + NRTI + II Tenofovir Raltegravir Etravirine 1398 <50
49 Peg-IFNα/RBV Telaprevir 24 2NRTI + II Tenofovir Emtricitabine Raltegravir 609 <50
95 Peg-IFNα/RBV Telaprevir 48 2NRTI + NNRTI Tenofovir Emtricitabine Etravirine 260 78
96 Peg-IFNα/RBV — 48 2NRTI + 2PI Tenofovir Emtricitabine Atazanavir/r 830 367
97 Peg-IFNα/RBV Telaprevir 48 2NRTI + II Tenofovir Emtricitabine Raltegravir 580 523
103 Peg-IFNα/RBV Telaprevir 48 2NRTI + NNRTI Emtricitabine Tenofovir Etravirine 304 <50
109 Peg-IFNα/RBV Telaprevir 48 2NRTI + NNRTI Lamivudine Abacavir Etravirine 1039 <50
114 Peg-IFNα/RBV — 48 2NRTI + NNRTI Tenofovir Emtricitabine Rilpivirine 1163 <50
115 Peg-IFNα/RBV — 48 2NRTI + NNRTI Tenofovir Emtricitabine Efavirenz 637 <50
133 Peg-IFNα/RBV — 48 2NRTI + PI Tenofovir Emtricitabine Atazanavir/r 597 <50
139 Peg-IFNα/RBV Telaprevir 48 2NRTI + II Raltegravir Lamivudine Abacavir 603 <50
148 Peg-IFNα/RBV — 36 2NRTI + II Tenofovir Emtricitabine Raltegravir 726 <50
174 Peg-IFNα/RBV — 48 PI Darunavir/r 840 <50
213 Peg-IFNα/RBV — 48 2NRTI + PI Lamivudine Abacavir Atazanavir/r 1118 <50
216 Peg-IFNα/RBV — 48 2NRTI + NNRTI Emtricitabine Efavirenz Tenofovir 1144 <50
432 Peg-IFNα/RBV Sofosbuvir 24 PI Darunavir/r 1150 <50
515 Peg-IFNα/RBV Sofosbuvir 24 2NRTI + II Tenofovir Emtricitabine Raltegravir 488 <50
711 Peg-IFNα/RBV — 48 2NRTI + II Abacavir Lamivudine Raltegravir 120 <50
718 Peg-IFNα/RBV Sofosbuvir 24 PI Darunavir/r 790 <50
719 Peg-IFNα/RBV Sofosbuvir 24 PI Darunavir/r 870 <50
721 Peg-IFNα/RBV — 36 2NRTI + II Lamivudine Abacavir Raltegravir 210 99000
722 Peg-IFNα/RBV — 48 2NRTI + II Tenofovir Emtricitabine Raltegravir 660 190
724 Peg-IFNα/RBV — 48 2NRTI + II Raltegravir Emtricitabine Tenofovir 350 <50
725 Peg-IFNα/RBV — 48 2NRTI + II Tenofovir Emtricitabine Raltegravir 1330 <50
726 Peg-IFNα/RBV — 48 2NRTI + II Lamivudine Abacavir Raltegravir 870 <50
729 Peg-IFNα/RBV — 48 2NRTI + II Tenofovir Emtricitabine Raltegravir 1150 <50
Table 2. Characteristics of the antiviral therapy in HIV/HCV-coinfected patients included in the study during 
the follow-up. Abbreviations: HCV, hepatitis C virus; HIV, human immunodeficiency virus; HIV-RNA, HIV 
plasma viral load; peg-IFNα, PEGylated interferon-alpha; RBV, ribavirin; DAAs, direct-acting antivirals; cART, 
combined antiretroviral therapy; NRTI, nucleoside analogue HIV reverse; NNRTI, non-nucleoside analogue 
HIV reverse transcriptase inhibitor; PI, protease inhibitor; II, integrase inhibitor.
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At week 24 after SVR, the same decreasing order for the AUC (Fig. 1C) and the ID50 (Fig. 1D) was observed. 
However, it is important to note that HCV-nAbs against S52 (3a) were not detected in any of the patients at week 
24 after SVR (Fig. 1C,D). Similarly, HCV-nAbs against JFH1 (2a) were also not detected in many patient samples 
from week 24 after SVR (Fig. 1C,D).
The impact of HCV clearance on the HCV-nAb titers was evaluated through an analysis of repeated measures 
(Fig. 2). We found significant decreases in AUC (p ≤ 0.05; Fig. 2A) and ID50 (p ≤ 0.05; Fig. 2B) values for all HCV 
recombinant viruses at week 24 after SVR, except for ID50 values from the S52 (3a) virus because all values were 
null.
To confirm that anti-HCV antibodies declined shortly after anti-HCV treatment, the reactivity of the 17 
plasma samples positive for HCV-GT1a was tested at baseline and week 24 after SVR against the purified E2 gly-
coprotein from H77 (HCV-GT1a) in an enzyme-linked immunosorbent assay. Like HCV-nAbs, total antibodies 
against E2 were substantially reduced at week 24 after SVR (Supplementary Fig. 3).
Correlation analysis among HCV-nAb titers against chimeric viruses. At baseline, the AUC values 
for a particular chimeric virus correlated positively with the corresponding values from the other chimeric viruses 
(Fig. 3). That is, patients with high HCV-nAb titers against a specific chimeric virus also had high titers against 
the other chimeric viruses (r > 0.4; p ≤ 0.05). The lowest correlations were found between S52 (3a) and J4 (1b), 
and between S52 (3a) and ED43 (4a) (Fig. 3). Similarly, a positive correlation was also observed among HCV-nAb 
titers (ID50) against H77 (1a), J4 (1B), JFH1 (2a), and ED43 (4a) (r > 0.4; p ≤ 0.05); while S52 (3a) did not show 
any correlation with the other chimeric viruses (Fig. 3).
At week 24 after SVR, HCV-nAb titers (AUC) against J4 (1b) and ED43 (4a) correlated positively with base-
line values for J4 (1b) and ED43 (4a) (r > 0.4; p ≤ 0.05), indistinctly (Fig. 3). This means that patients with the 
highest HCV-nAb titers at the end of follow-up were those who also had the highest HCV-nAb titers at baseline. 
Furthermore, at week 24 after SVR, HCV-nAb titers against H77 (1a) correlated with HCV-nAb titers against J4 
(1b), JFH1 (2a), and ED43 (4a); and HCV-nAb titers against J4 (1b) also correlated with HCV-nAb titers against 
ED43 (4a) (Fig. 3). When we analyzed the correlations among ID50 values, a similar pattern as that observed for 
the AUC values was found, but the number of relevant correlations was lower (Fig. 3).
correlation among clinical data and HcV-nAb titers. At baseline, we found a significant positive 
relationship between the CD4/CD8 ratio and the HCV-nAb titers against H77 (1a) (AUC [r = 0.454; p = 0.013] 
and ID50 [r = 0.450; p = 0.014]). However, we did not find any correlation between the CD4/CD8 ratio and the 
HCV-nAb titers at the end of the study (see Supplementary Table 3). We also looked for correlations with other 
clinical variables (age, nadir CD4+ T cells/mm3, CD4+ T cells/mm3, log10 HCV-RNA, and LSM), but no signifi-
cant association was found (data not shown).
Figure 1. Summary of the neutralization potency of HCV antibodies against recombinant viruses in HIV/
HCV-coinfected patients, at baseline and 24 weeks after sustained virological response. Individual (circles) and 
median values (short horizontal bars) are represented. Abbreviations: AUC, area under the curve (arbitrary 
units); ID50, 50% inhibitory dose; SVR, sustained virological response; Wk, week. Statistics: p-values were 
calculated by the Wilcoxon test.
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Discussion
HCV co-infection has a high impact on the morbidity and mortality among HIV infected patients as a result of a 
more aggressive progression of liver fibrosis and cirrhosis21–24. In this population, successful anti-HCV treatment 
with peg-IFN and ribavirin had a positive impact on these conditions25–27, and treatment with DAAs improved 
patient-reported outcomes28–30. However, other relevant outcomes associated with HCV elimination in HIV/
HCV-coinfected patients remain to be investigated.
Figure 2. Impact of HCV clearance on HCV-nAb titers in HIV/HCV-coinfected patients who achieved 
sustained virological response. Abbreviations: AUC, area under the curve (arbitrary units); ID50, 50% 
inhibitory dose; SVR, sustained virological response; Wk, week. Statistics: p-values were calculated by the 
Wilcoxon test. Median values of AUC and ID50 are shown under each aligned dot plot.
Figure 3. Summary of relevant correlation coefficients (r > 0.4; p < 0.05) among HCV-nAb titers against 
recombinant viruses in HIV/HCV-coinfected patients at baseline and 24 weeks after sustained virological 
response. The correlation coefficients are denoted by the intensity of the color and the size of the circle. 
Abbreviations: AUC, area under the curve (arbitrary units); ID50, 50% inhibitory dose; SVR, sustained 
virological response; Wk, week. Statistics: Correlation coefficients and p-values were calculated by the test of 
Spearman’s correlation coefficient.
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Since HCV-nAbs correlate with protection and virus clearance31, it is important to know how treatment-mediated 
HCV elimination may influence HCV-nAb titers after therapy. In the present study, we found several things to 
be true. First, most of the HIV/HCV-coinfected patients had high titers of broad HCV-nAbs at baseline, but 
these titers declined significantly 24 weeks after SVR, particularly for JFH1 (2a) and S52 (3a) viruses, against 
which HCV-nAbs were generally not detected at that time. Second, patients with high HCV-nAb titers against 
a particular genotype also had high titers against the other genotypes and retained moderately high HCV-nAb 
titers at the end of follow-up. HCV-nAb titers against S52 (3a) showed the worst correlation with HCV-nAb titers 
against the other genotypes. Third, the CD4/CD8 ratio correlated positively with HCV-nAb titers against H77 
(1a). Overall, by measuring potency and breadth of HCV-nAbs, our study provides functionally relevant results, 
as these antibodies are correlated with HCV protection13–17 and HCV clearance8–12. To our knowledge, this is the 
first study that analyzes the evolution of HCV-nAbs in a cohort of HIV/HCV-coinfected patients who eliminated 
HCV infection after HCV therapy.
The high degree of genetic diversity of HCV is a major impediment to vaccine development7. This genetic 
heterogeneity is particularly relevant in the envelope glycoproteins (E1 and E2), where amino acid sequences vary 
up to 30% between HCV genotypes, 20% within genotypes, and 10% within subtypes31. Defining the neutralizing 
breadth of cross-reactive anti-HCV antibodies is critical to understanding the protective capacity against different 
HCV genotypes. In this study, most of the patients showed high levels of broad-spectrum HCV-nAbs at base-
line. Overall, the HCV-nAb titers (both AUC and ID50) were as follows: J4 (1b) > ED43 (4a) > H77 (1a) > JFH1 
(2a) > S52 (3a). This response pattern has been previously described in patients monoinfected by HCV, possibly 
due to strain-specific, rather than genotype-specific effects on the induction of HCV-nAbs31. Thus, the neutral-
izing activity of a patient’s plasma was not dictated primarily by his infecting HCV genotype, since, for example, 
plasma from patients infected with HCV genotype 1a or 1b neutralized HCV chimeric virus for genotype 4 quite 
efficiently. However, it should be noted that chimeric viruses from HCV genotypes 2a and 3a were neutralized 
with less efficiency, regardless of the HCV genotype of the patient. Although a correlation between the genetic 
distance of the infecting viruses and the neutralizing capacity of the anti-HCV antibodies from the infected 
patients was not found, an important point to consider is that more than one infecting genotype has been detected 
in five individuals. This strongly suggests that different HCV genotypes might have infected most patients along 
the course of their chronic infections. This probably has contributed to the development of broad-spectrum 
HCV-nAbs.
Another relevant finding of our work was a significant decrease in HCV-nAb titers at week 24 after SVR, 
suggesting that continuous exposition to HCV antigens is necessary to maintain high HCV-nAb titers. In our 
study, the number of patients with very low HCV-nAb titers increased at the end of follow-up, particularly for 
JFH1 (2a) and S52 (3a) viruses. However, although the drop in HCV-nAb titers was more pronounced in the 
case of H77 (1a), J4 (1b), and ED43 (4a), titers against these viruses remained relatively high at week 24 after 
SVR. This was because titers against these viruses were usually higher than against the other viruses at baseline. 
There is not much information on the dynamics of antibodies against HCV in patients who eliminated HCV 
infection. Wiegand et al. found a rapid decrease of anti-HCV antibodies in patients with acute hepatitis C who 
were treated with IFN-α-2b and eliminated the HCV infection32. However, patients chronically infected with 
HCV who eliminated HCV infection after IFN therapy had a slow decrease, which may be prolonged for several 
years32–38. A rapid decrease of anti-HCV antibodies was also reported in HIV/HCV-coinfected individuals follow-
ing peg-IFN-α/ribavirin treatment during acute, but not chronic, HCV infection39,40. In contrast, our study shows 
a quick drop in HCV-nAbs following peg-IFN-α/ribavirin treatment of chronic HCV-infected patients coinfected 
with HIV. Note that an important difference between our study and previous reports is that all these preceding 
studies evaluated total antibodies against HCV by commercial semiquantitative immunoassays. In contrast, we 
evaluated HCV-nAbs or anti-E2 antibodies by quantitative methods in which serial dilutions of plasma samples 
were tested. Titers and breadth of HCV-nAbs might more accurately reflect the efficacy of the humoral immune 
response and the capacity of the patient to be protected from HCV reinfections. Thus, the decline of HCV-nAbs 
observed in our study after anti-HCV therapy in HIV/HCV-coinfected individuals may be one of the reasons for 
the very high HCV reinfection rates observed in this population, highlighting the impact of being HIV positive 
on the probability of HCV reinfection41.
HIV infection leads to the destruction and functional impairment of CD4+ T-cells, which may lead to dys-
function of the HCV-specific humoral immune response42. The CD4/CD8 ratio describes the overall immune 
dysfunction in HIV-infected patients since a low or inverted CD4/CD8 ratio is associated with altered immune 
function, chronic inflammation, and immune senescence43,44. In our study, a positive correlation between the 
CD4/CD8 ratio and the HCV-nAb titers was observed for H77 (1a) at baseline, but not at the end of follow-up. In 
agreement with this, a CD4+ T-cell-dependent reduction of HCV-nAbs has been reported in patients previously 
infected with HCV following incident HIV infection45. Additionally, Lee et al. found that HCV-nAbs against 
JFH-1 correlated positively with baseline CD4+ T-cell counts and increased after cART in HIV/HCV-coinfected 
patients, regardless of the baseline CD4+ T-cell counts46. In addition to the T-cell, HIV infection induces dys-
regulation of B cells and damage of lymphoid organs, which endangers the humoral immune response47–50. Loss 
of memory B cells in HIV-infected patients has been amply documented51–53, and it has been associated with 
impaired immunization responses and reduced long-term serologic immunity to measles and Streptococcus 
pneumoniae54,55. Importantly, antiretroviral therapy did not restore serologic memory in primary or in chronic 
infection55. These results are in line with our observation that HCV-nAbs decrease short after HCV therapy 
in HIV-infected patients undergoing ART, in contrast to what has been observed in patients infected only 
with HCV32–38. Immunoglobulin class switching also seems to be impaired in HIV infections56,57, which might 
result in the production of antibodies with reduced affinity maturation and limited neutralizing breadth58,59. 
Conversely, in the present study, a broadly neutralizing antibody response against HCV has been observed in 
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HIV/HCV-coinfected patients. However, additional neutralization experiments with a larger panel of HCVs and 
with plasma samples from HCV-monoinfected patients are necessary to clarify this point.
Limitations of the study. Firstly, this study has a retrospective design, data were collected retrospectively, 
and patients included in this study met a set of criteria for starting HCV treatment (see Patients and Methods), 
which may have introduced a selection bias. Secondly, this study has a limited number of patients, although 
the design with repeated measures considerably improves the statistical power of the study. Thirdly, a group of 
HCV-monoinfected patients was not used as a comparator to HIV/HCV-coinfected patients. Although it was not 
possible to include this group in our study, we would like to emphasize that several studies have reported a slow 
decrease of anti-HCV antibody titers following the anti-HCV treatment that may take several years32–38. However, 
these studies used semiquantitative assays and did not measure neutralizing antibodies, as it has been done in 
the present work. Fourthly, since peg-IFN-α + ribavirin therapy may have immunomodulatory effects affecting 
HCV-nAb titers, further studies using DAAs alone are needed. Fifthly, we did not evaluate the level of protection 
offered by the neutralizing antibodies measured in this study. This is an important issue, and the answer to this 
question will be highly relevant for the development of an antibody-based vaccine against HCV and to under-
stand viral reinfections. Sixthly, although it has been shown that antibody titers decline after SVR, no information 
on memory B cell population nor residual liver immunity has been analyzed. Finally, we have used a reduced 
panel of recombinant HCVs for neutralization tests. The use of a larger and diverse panel of viruses could have 
added additional information on some aspects of the results.
conclusions
In conclusion, high titers of broad-spectrum HCV-nAbs were observed in HIV/HCV-coinfected individuals. 
These titers, however, declined soon after SVR. Our results suggest that those individuals may not be able to 
maintain protecting anti-HCV antibodies after elimination of HCV by treatment. This should be taken into 
account in the development of potential anti-HCV vaccines.
patients and Methods
Study subjects. We performed a retrospective study (before-and-after design) in 29 HIV/HCV-coinfected 
patients from the cohort of “Grupo de Estudio del SIDA” (GESIDA 3603b study, Spain; see Appendix), which 
has been previously described60. All patients were treated with pegylated interferon-alpha plus ribavirin (peg-
IFNα + ribavirin) or peg-IFN-α/ribavirin/DAAs between February 2012 and February 2014 and had an SVR 
assessment at 24 weeks after the end of HCV treatment.
Clinical, epidemiological, and virological characteristics of each patient were collected prospectively60. 
This study was performed according to the Declaration of Helsinki and was approved by the Research Ethics 
Committee of the Instituto de Salud Carlos III (CEI PI 23_2011) and participating centers. The participants gave 
their informed consent before enrollment.
We used plasma samples from baseline (between one week before starting the anti-HCV treatment and the 
same day at which the treatment was initiated) and the end of follow-up (week 24 after SVR, which corresponds 
to week 48 after the end of HCV treatment) for each patient.
HCV genotyping. All samples were processed using the Abbott-Real Time-HCV genotype II (Abbott 
Laboratories, Illinois, USA) according to manufacturer instructions. First, viral RNA was extracted from 200µl of 
plasma sample using the QIAsymphony instrument, the commercial mini kit DSP Virus/Pathogen, and the pro-
tocol Cellfree 200 v.7. (Qiagen, Hilden, Germany). Internal, positive and negative controls from Abbott-RT-HCV 
II kit were incorporated into the extraction process. Then, multiplexed RT-PCR reactions were performed using 
the kit amplification reagent packs and the Abbott m2000rt instrument.
E1 and E2 sequencing and phylogenetic analysis. The viral RNA extracted for HCV geno-
typing was used to amplify the E1E2 from eight 1a patient-derived viruses. A nested RT-PCR was car-
ried out using the Qiagen OneStep RT-PCR Kit (Qiagen, Hilden, Germany) following manufacturer’s 
instructions with the following pairs of primers (numbering reference to GenBank accession AF011751)61: 
5′GGACGGGGTAAACTATGCAACAGG3′ (nucleotide position 818–841), 5′GGGATGCTGCATTGAGTA3′ 
(nucleotide position 2599–2616), 5′CACCATGGGTTGCTCTTTTTCTATC3′ (nucleotide position 843–869) and 
5′TTACGCCTCCGCTTGGGATATGAGTAACATCAT3′ (nucleotide position 2550–2582). The PCR products 
were sequenced by the Sanger method with the previous inner forward and reverse primers and two additional 
primers: 5′AGSGTAYTWYTCCATGG3′ (nucleotide position 1418–1434) and 5′CARCCRAACCARTTGCCC3′ 
(nucleotide position 1996–1979).
Phylogenetic analyses were performed using a total of 34 E1/E2 sequences corresponding to different HCV 
1 obtained from GenBank public database (KP098533.1, AF009606, M62321, M67463, HQ850279, EF407457, 
D90208, M58335, EU781827, EU781828, D14853, AY051292, AY651061, KJ439768, KC248194, AM910652, 
KC248198, KC248199, KJ439772, KJ439773, KC248193, KC248196, KJ439778, KJ439782, KJ439775, KJ439781, 
KJ439774, HQ537007, AJ851228, KJ439780, KJ439779, KJ439776, KJ439777, NC 004102.1) and 8 E1/E2 
sequences from HCV 1a infected patients. The evolutionary history was inferred using the Neighbor-Joining 
method62, a bootstrap test with 1000 replicates63 and the Maximum Composite Likelihood method64. 
Evolutionary analyses were conducted in MEGA765. Moreover, the same analyses for these infected patients were 
performed with E1/E2 sequences from chimeric HCV (AB047639.1, EU204645.1, EU363760.1, EU363761.1, 
FJ230881.1) and a reference HCV 1a (isolate H77) (NC 004102.1).
cells and viruses. Human hepatoma Huh7.5 cells were obtained from Apath LLC (760 Parkside Ave. 
Brooklyn, NY 11226, USA) and Huh7.5.1 clone 2 from F Chisari (The Scripps Research Institute, La Jolla, USA). 
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Cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine 
serum, 4 mM L-glutamine, 100 U/ml penicillin, and 100 U/ml streptomycin (DMEM10) at 37 °C in a 5% CO2 
atmosphere. Plasmids encoding JFH1-based chimeric HCV genotypes 1a (H77/JFH1)66, 1b (J4/JFH1)67, 3a (S52/
JFH1)68, and 4a (ED43/JFH1)66 were gifts from Jens Bukh (University of Copenhagen, Copenhagen, Denmark). 
The plasmid encoding HCV JFH1 (genotype 2a)69 was obtained from Apath LLC. Plasmids were linearized with 
Xba I, transcribed in vitro with the MEGAscript T7 kit (Invitrogen, Thermo Fisher, Rockford, IL, USA), and 
viruses were produced by electroporation of the resulting genomic RNA into Huh7.5.1 clone 2 cells.
HCV neutralization assay. A total of 12,000 Huh7.5 cells per well were plated in flat-bottom 96-well tissue 
culture plates and incubated overnight at 37 °C. The following day, 150 focus-forming units of chimeric HCVs 
were mixed with an equal volume of 1:2 serial dilutions (starting at a 1:50 dilution) of the plasma sample or a con-
trol plasma from a healthy donor in DMEM10, incubated at 37 °C for 1 hour and then added to cells. After three 
days of infection, the cells were fixed with cold methanol for 10 minutes, followed by a one-hour incubation with 
the anti-NS5A 9E10 antibody (a gift from Charles Rice, The Rockefeller University, New York, USA). Foci were 
visualized after one-hour incubation with an anti-mouse IgG horseradish peroxidase-linked whole secondary 
antibody (Abcam, Cambridge, UK) and 3-amino-9-ethylcarbazole (Sigma, St. Louis, MO, USA) and counted 
under a light microscope. Percentage of neutralization at each antibody dilution was calculated as [1- (foci in 
the presence of plasmatest/foci in the presence of plasmacontrol)] × 100%. With these data, titration curves for each 
type of virus were made using GraphPad Prism 7.00 for Windows (GraphPad Software, La Jolla, California USA). 
The 50% inhibitory dose (ID50) was calculated as the dilution of plasma that resulted in a 50% reduction in the 
number of foci. The area under the curve (AUC) was also calculated to quantify neutralization potency70 by using 
GraphPad Prims 7.00 and the following parameters: Baseline Y = 0; ignore peaks that are less than 10% of the 
distance from minimum to maximum Y; all peaks must go above the baseline. The AUC is expressed as X units 
times the Y units.
Production of HCV-E2 (H77) and quantitative enzyme-linked immunoassay. The ectodomain 
of E2 glycoprotein from genotype 1a (H77) was produced using the baculovirus/insect cell system according to 
a previously described procedure71 with slight modifications. Briefly, the DNA encoding the ectodomain of E2 
(H77) protein, residues 384–661 (E2661) with the addition at the 5′ end of a six-histidine tag coding sequence, 
was inserted into the baculovirus transfer vector pAcGP67A (Pharmingen, San Diego, CA, USA) to create the 
recombinant plasmid pAcGP67A-E2661-H77. Insect Spodoptera frugiperda (Sf9) cells were cotransfected with 
flashBAC GOLDTM DNA (Oxford Expression Technologies, Oxford, UK) and the recombinant transfer vec-
tor pAcGP67A–E2661-H77 as indicated by the manufacturer. The protein was expressed by infecting High Five 
cells in Insect X-Press serum-free media with high titter virus (>108 pfu/ml) at MOI of 5–10. Medium with the 
secreted recombinant glycoprotein was collected approximately 120 h postinfection, dialyzed against 50 mM 
Tris-HCl pH 8.0, 50 mM NaCl, and loaded onto a Ni2+ -nitrilotriacetic acid-agarose column (Qiagen, Hilden, 
Germany). The recombinant E2661 protein was eluted with 200 mM imidazole in dialysis buffer.
Ninety-six-well microtiter plates were coated with 500 ng Galanthus nivalis lectin (GNA, Sigma, St. Louis, 
MO, USA) at 4 °C overnight, followed by blocking with 2% porcine serum in PBS. Then 40 ng of purified E2 were 
added to the wells for 2 h at room temperature, followed by incubation with plasma sample dilutions in blocking 
solution (dilution factor 2, initial dilution 1:50), anti-human IgG-Peroxidase (GE, Healthcare, Buckinghamshire, 
UK) and substrate (OPD, Sigma, St. Louis, MO, USA). Extensive washing with water was done after each step. 
Optical density was read at 492 nm.
Statistical analysis. The statistical analysis was performed with the Statistical Package for the Social 
Sciences (SPSS) 23.0 software (IBM Corp., Chicago, USA). Statistical significance was defined as p < 0.05. All 
p-values were two-tailed. The Wilcoxon test was used to analyze the paired samples within each group. The cor-
relation was analyzed using the test of Spearman’s correlation coefficient.
Data Availability
All relevant data are within the paper and Supporting Information files. For additional information, interested 
readers can contact Dr. Isidoro Martinez at imago@isciii.es.
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